CatalystPit
TerminalPit ConsensusInsidersPoliticiansInstitutionsNewsScreener

CADLCandel Therapeutics, Inc.

NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Last close $10.44 · 2026-09-30
ABOUT
ExchangeNASDAQ
SectorHealthcare
IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Market cap$798.85M
CountryUSA
RECENT INSIDER TRADES
  • 2026-09-11 · Tak Paul Peter (Chief Executive Officer) · SELL
  • 2026-09-11 · Tak Paul Peter (Chief Executive Officer) · OTHER
  • 2026-08-19 · Tyagarajan Seshu (Chief Technology Officer) · SELL
  • 2026-07-01 · Tyagarajan Seshu (Chief Technology Officer) · SELL
INSTITUTIONAL OWNERSHIP
Institutional holders145
Shares held55,709,200
Value$550.75M
Percent of shares outstanding72.80%
As of quarter end2026-06-30
RECENT NEWS
  • Candel Therapeutics to present cancer immunotherapy data at SITC 2026
  • Candel Therapeutics grants stock options to 4 new employees
  • Candel Therapeutics publishes Phase 2a data showing 24.5-month survival in NSCLC
  • CADL: Candel Therapeutics Announces New Data Showing Sustained Immune Remodeling More Than Two Years After Aglatimagene Besadenovec Treatment in Localized Prostate Cancer at ASTRO 2026
  • Candel Therapeutics: Strong Buy On Aglatimagene Prostate Cancer BLA Filing In Q4
CatalystPit
FeaturesComing soonPricingComing soonPrivacyTermsDisclaimerAffiliate TermsContact
2026 CATALYSTPIT · NOT FINANCIAL ADVICE · DELAYED FILINGS